Blowing the Whistle at the FDA, Jan 2001, exposing Dearborn and how OspA causes immunosuppression rather than, "was a vaccine."
 


01 Oct 2017

Home


File List, RICO

1988 Steere says Lyme is like a B cell leukemia

Assoc Blogs-n-Webs:
TruthCures.org
badlymeattitude.com/
immune2lies.com/
researchfraud.com/
may12.org
meadvocacy.org/
truthbetoldx81
lymecryme
CrymeDiseaseNorway
crymedisease
theothersideofthestretcher
rjspiritualityandtuth
LymeTruthSite

JC-LilnkedIn
KD-Linkedin.com
LD-LinkedIn
JC-academia.edu

KD-academia.edu

 


CDC "SPIDER"

Fungal Exosomes Inhibit Apoptosis

IDSA: "Vaccines serve the mfgs, not their victims"

RICO_filed_USDOJ

BlumenthalAntiTrust Lawsuit

Exosomes, Blebs

Spirochetal_Dementia


PDFs
CDC Admits Fraud, 2016
Dattwyler, 1988
Golightly, 1988
Dressler, 1994
BarbourFish, 1993
Dearborn, 1994
BarbourFishpdf.pdf
 

Pathogenic Fungi

Bush's warcrimes, Oct 2000

Trainer

170708

 



BACK TO THE 1989 IDSA REVIEWS, SPECIAL SUPPLEMENT

Included in that Supplement are these articles about syphilis and spirochetes in general


 

 
The above full text scanned in report is associated with this abstract:

Rev Infect Dis. 1989 Sep-Oct;11 Suppl 6:S1511-7.Links

Treatment of syphilis: current recommendations, alternatives, and continuing problems.

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Benzathine penicillin continues to be the cornerstone of recommended therapy for syphilis. Recent increases in the syphilis rates in the United States and concerns about the adequacy of currently recommended therapy for syphilis in patients with concomitant human immunodeficiency virus infection have stimulated reappraisal of alternatives to currently recommended therapy. Desirable features of antimicrobial agents for syphilotherapy include long serum half-life, good penetration into the central nervous system, and ease of administration. Benzathine penicillin provides prolonged treponemicidal levels of penicillin G in serum but does not reliably produce adequate levels of penicillin in the central nervous system. Tetracycline requires multiple daily dosing, has relatively frequent adverse effects, and has unproven efficacy for central nervous system involvement. Erythromycin, which may be less active than tetracycline for syphilis therapy, has similar shortcomings. Recent evaluations of ceftriaxone for early syphilis therapy are promising; however, the optimal dose and duration of therapy are unknown. No currently recommended therapy for syphilis is clearly optimal for reliable, cost-effective therapy. Careful reappraisal of currently available syphilotherapy and alternatives is needed.  PMID: 2682964 [PubMed - indexed for MEDLINE]

 

 

 

 
The above full text scanned in report is associated with this abstract:

Rev Infect Dis. 1989 Sep-Oct;11 Suppl 6:S1511-7.Links

Treatment of syphilis: current recommendations, alternatives, and continuing problems.

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Benzathine penicillin continues to be the cornerstone of recommended therapy for syphilis. Recent increases in the syphilis rates in the United States and concerns about the adequacy of currently recommended therapy for syphilis in patients with concomitant human immunodeficiency virus infection have stimulated reappraisal of alternatives to currently recommended therapy. Desirable features of antimicrobial agents for syphilotherapy include long serum half-life, good penetration into the central nervous system, and ease of administration. Benzathine penicillin provides prolonged treponemicidal levels of penicillin G in serum but does not reliably produce adequate levels of penicillin in the central nervous system. Tetracycline requires multiple daily dosing, has relatively frequent adverse effects, and has unproven efficacy for central nervous system involvement. Erythromycin, which may be less active than tetracycline for syphilis therapy, has similar shortcomings. Recent evaluations of ceftriaxone for early syphilis therapy are promising; however, the optimal dose and duration of therapy are unknown. No currently recommended therapy for syphilis is clearly optimal for reliable, cost-effective therapy. Careful reappraisal of currently available syphilotherapy and alternatives is needed.  PMID: 2682964 [PubMed - indexed for MEDLINE]